| Patients with CAE, n (%) | BR | B-mono |
|
| n = 275 | n = 100 |
| Duration of the line of therapy (days), mean [median] | 121 [116] | 75 [56] |
| Blood and lymphatic system disorders | 201 (73.1) | 67 (67.0) |
| Anemia (deficiency and hemolytic) | 73 (26.5) | 35 (35.0) |
| Neutropenia and febrile neutropenia | 112 (40.7) | 37 (37.0) |
| Lymphadenopathy | 62 (22.5) | 18 (18.0) |
| Thrombocytopenia (including autoimmune) | 78 (28.4) | 25 (25.0) |
| Cardiac disorders | 75 (27.3) | 21 (21.0) |
| Arrhythmia (including atrial fibrillation and flutter) | 58 (21.1) | 12 (12.0) |
| Cardiac failure congestive | 35 (12.7) | 11 (11.0) |
| Endocrine disorders, i.e., hypothyroidism | 47 (17.1) | 6 (6.0) |
| Gastrointestinal disorders | 162 (58.9) | 48 (48.0) |
| Nausea/vomiting | 97 (35.3) | 34 (34.0) |
| General disorders | 139 (50.5) | 47 (47.0) |
| Chills/pyrexia (with and without fever) | 50 (18.2) | 21 (21.0) |
| Malaise and fatigue | 78 (28.4) | 25 (25.0) |
| Hepatobiliary disorders | 1 (0.4) | 0 (0.0) |
| Injury, poisoning and procedural complications | 34 (12.4) | 21 (21.0) |
| Allergic reaction + application/administration site reaction | 30 (10.9) | 20 (20.0) |
| Metabolism and nutrition disorders | 114 (41.5) | 28 (28.0) |
| Dehydration | 54 (19.6) | 18 (18.0) |
| Hypokalaemia | 25 (9.1) | 4 (4.0) |
| Musculoskeletal and connective tissue disorders | 69 (25.1) | 17 (17.0) |
| Neoplasms | 97 (35.3) | 24 (24.0) |
| Nervous system disorder | 50 (18.2) | 10 (10.0) |
| Renal and urinary disorders | 71 (25.8) | 15 (15.0) |
| Psychiatric disorders | 35 (12.7) | 12 (12.0) |
| Respiratory, thoracic and mediastinal disorders | 136 (49.5) | 43 (43.0) |
| Cough | 60 (21.8) | 19 (19.0) |
| Dyspnea | 69 (25.1) | 20 (20.0) |
| Skin and subcutaneous tissue disorders | 26 (9.5) | 5 (5.0) |
| Vascular disorders | 156 (56.7) | 39 (39.0) |
| Hypertension | 134 (48.7) | 31 (31.0) |
| Infections | 141 (51.3) | 39 (39.0) |